<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03751917</url>
  </required_header>
  <id_info>
    <org_study_id>APL0618</org_study_id>
    <nct_id>NCT03751917</nct_id>
  </id_info>
  <brief_title>Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia</brief_title>
  <acronym>APL0618</acronym>
  <official_title>A Long-Term Retrospective and Prospective Safety Study of Arsenic Trioxide in Patients With Newly Diagnosed, Low- to Intermediate-Risk Acute Promyelocytic Leukemia (APL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The therapeutic advantage of the association of ATRA + Arsenic Trioxide is more favorable and
      manageable as compared to ATRA + chemotherapy. Nevertheless, at present, there is not enough
      information on the incidence of long-term side effects.

      This study, as well as other similar studies conducted around Europe, will focus on following
      patients treated with this therapy on a long-term basis.

      Once all studies in Europe will be concluded, all data will be analyzed together.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Considering the clear therapeutic advantage associated with ATRA+ATO combination therapy and
      the more favorable and overall manageable safety profile compared to ATRA+chemotherapy, the
      benefits of the combination in the first-line indication do appear to overweigh the risks.

      However, no information regarding the actual adverse event (AE) incidence and the long-term
      toxicity of ATRA+ATO is available at present and therefore, as a postmarketing commitment,
      TEVA (the Company holding the Marketing Authorisation of Trisenox® (Arsenic trioxide)) is
      setting up a long-term safety cohort study of Trisenox in newly diagnosed low- to
      intermediate-risk APL patients retrospectively analyzing data from APL disease registries all
      around Europe.

      As a result, this observational study is part of the retrospective PASS Study (A
      Post-Authorisation Long-Term Retrospective Safety Cohort Study of Arsenic Trioxide in First
      Line Low-to Intermediate-Risk Acute Promyelocytic Leukaemia Patients) that will use data from
      multinational APL disease registries in Europe. The present study will focus on Italian
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of grade III/IV (Common Terminology Criteria for Adverse Events (CTCAE) v4.03) adverse events of special interest (AESI).</measure>
    <time_frame>At a maximum of 5 years from study entry</time_frame>
    <description>AESI are, among others: differentiation syndrome, creatinine, bilirubin, neurotoxicity, aspartate amino transferase/alanine amino transferase (ASAT/ALAT) ratio, haemorrhage, sepsis, QTc prolongation, cardiac events including congestive heart failure (CHF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of unexpected serious adverse events (SAEs).</measure>
    <time_frame>At a maximum of 5 years from study entry</time_frame>
    <description>Including grading and relationship as documented in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients developing secondary malignancies.</measure>
    <time_frame>At a maximum of 5 years from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients developing therapy-related myelodysplastic syndrome (tMDS).</measure>
    <time_frame>At a maximum of 5 years from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients developing acute myeloid leukemia (tAML).</measure>
    <time_frame>At a maximum of 5 years from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who die.</measure>
    <time_frame>At a maximum of 5 years from study entry</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>APL patients</arm_group_label>
    <description>The study will be conducted using multinational data from disease registries for APL. The study participants will consist of patients with newly diagnosed, low-to intermediate-risk APL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide</intervention_name>
    <description>This is an observational study. Patients who have received or are receiving all trans retinoic acid (ATRA) + Arsenic Trioxide will be followed and analyzed.</description>
    <arm_group_label>APL patients</arm_group_label>
    <other_name>ATRA+ATO</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Source Population for the study is patients included in existing multinational disease
        registries for APL in Europe. APL registries collect real-world data on APL demographics
        and provide information on disease characteristics, treatment patterns and long-term
        effects. Participating physicians are not subject to any instructions with regard to the
        diagnosis and therapy of their patients. All patient treatment is carried out within
        routine clinical practice at the discretion of the physician and according to existing
        treatment guidelines.

        Data will be extracted from the registries for all patients meeting the above inclusion and
        exclusion criteria to provide the study population.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  APL diagnosis based on cytological criteria and confirmed by the presence of the
             (15;17) translocation and/or the presence of the PML/RARA rearrangement (with the
             determination of the breakpoint subtype).

          -  Newly diagnosed low- to intermediate-risk APL (white blood cells [WBC] count
             ≤10x103/µL)

          -  First line treatment with ATRA+ATO

          -  Aged 18 years or above

          -  Signed informed consent, if applicable

        Exclusion Criteria:

          -  High risk APL (WBC count &gt; 10x103/µL)

          -  APL relapse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Lo Coco</last_name>
    <role>Study Chair</role>
    <affiliation>Università degli Studi - Policlinico di Tor Vergata</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>+39 0670390514</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>+39 0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - A.O. - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Ladetto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto-Universita' degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Specchia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Rambaldi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Rossi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTMO - Ematologia - Ospedale &quot;Binaghi&quot;</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Cabras</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - U.O. di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Molica</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Ematologia 1 e 2 IRCCS AOU San Martino-IST</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Angelucci</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Osp. Maggiore Policlinico UOC Oncoematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Cortelezzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot; - SC Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Cairoli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Ciceri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S.Gerardo&quot;</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Pioltelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Napoli Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Ferrara</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabbiano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Pescara</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita' &quot;Sapienza&quot; - Dip Biotecnologie Cellulari - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>De Stefano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita' degli Studi - Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Arcese</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesco Lo Coco</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Lo Coco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>stituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Cascavilla</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Ematologia 2 A.O. Citta' della Salute S. G. Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Vitolo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ULSS N.6 Osp. S. Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruggeri</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>November 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>November 22, 2018</last_update_submitted>
  <last_update_submitted_qc>November 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute promyelocytic leukemia</keyword>
  <keyword>Adults</keyword>
  <keyword>Arsenic trioxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

